- Home
- PHM vs INSM Comparison
PHM vs INSM Comparison
Compare PHM & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHM | INSM |
|---|---|---|
| Founded | 1950 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7B | 22.4B |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PHM | INSM |
|---|---|---|
| Price | $116.26 | $104.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 24 |
| Target Price | $140.80 | ★ $197.74 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 10-22-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.27 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $198.15 |
| Revenue Next Year | $3.97 | $59.04 |
| P/E Ratio | $26.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $108.49 | $90.39 |
| 52 Week High | $144.50 | $212.75 |
Technical Indicators
Market Signals| Indicator | PHM | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 30.92 |
| Support Level | $114.88 | $97.66 |
| Resistance Level | $122.56 | $119.54 |
| Average True Range (ATR) | 2.71 | 4.87 |
| MACD | -0.07 | -2.09 |
| Stochastic Oscillator | 37.01 | 13.19 |
Price Performance
Historical ComparisonAbout PHM PulteGroup Inc.
PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.